Outsourced Pharma White Papers

  1. Engineering Reliability In Cell Therapy Manufacturing 2/3/2026

    A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.

  2. Continuous Flow — An Emerging Alternative 5/16/2024

    Gain insights on transitioning from batch to continuous flow processes, the benefits of continuous flow chemistry, and ensuring regulatory compliance with Quality by Design (QbD) principles.

  3. Flexible Fill/Finish Solutions To Bridge The Clinical-To-Commercial Gap 7/23/2025

    As biopharma complexity grows, flexible CDMOs are essential for navigating evolving fill/finish needs, accelerated timelines, and regulatory uncertainty with agility and expertise.

  4. The Role Of A Consulting Firm In The IND Process 6/10/2025

    Navigate the complex IND process with expert guidance and discover how early FDA engagement can accelerate your path to clinical trials.

  5. Advancing Chronic Care Through GLP‑1 Innovation 1/23/2026

    GLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.

  6. Project Management: Sphere Of Influence 10/21/2024

    The project manager's sphere of influence extends beyond the project team, encompassing the organization, industry, and professional discipline.

  7. Safety, Containment, And Analysis Of Highly Potent Compounds 5/16/2024

    Explore a comprehensive overview of the challenges, requirements, and best practices for safely working with highly potent compounds in drug development and manufacturing.

  8. Building the Next Generation of TIDES Manufacturing Excellence 2/12/2026

    Rising demand for complex TIDES therapies is shifting manufacturing expectations, driving adoption of continuous processing, digital tools, stronger supply strategies, and greener, scalable synthesis.

  9. Smart Scaling For Cell And Gene Therapies 2/5/2026

    To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.

  10. Manufacturing Of Cytotoxic And Non-Cytotoxic Drugs In A Multiproduct Facility 10/16/2024

    The experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.